With the FDA set to make a decision on Shire plc's enzyme replacement therapy velaglucerase by the end of this month and a review date for Protalix Biotherapeutics Inc.'s Uplyso (taliglucerase alfa) expected later this year, Genzyme Corp.'s top-selling drug for Gaucher disease is certain to take a sales hit. (Bioworld Today) Read More
